FDA Approves USA’s First Interchangeable Biosimilar Insulin Product for Diabetes

The Food and Drug Administration of the United States have now approved the first interchangeable biosimilar insulin product, that is mainly indicated for the purpose of improving the glycemic control in the pediatric and adults affected from the Type 1 diabetes and in the adults affected with Type 2 diabetes.

The product ‘Semglee’ has been both interchangeable and biosimilar along with the reference product known as Lantus, which has been a long-acting insulin analog, and the Semglee has been the first interchangeable biosimilar product, that has been approved in the United States for the purpose of treating the patients suffering from diabetes, and the approval of these types of insulin products can be responsible in providing the patients with the options such as safe, high-quality, safe and low cost for the treatment of diabetes.

Janet Woodcock, acting commissioner of US FDA said, this has been a great news for the people who are relying on the insulin daily for the treatment of diabetes, as the interchangeable biosimilar and biosimilar products generally have the potential for greatly decreasing the costs of the healthcare.

Janet Woodcock also said, this approval has been the longstanding commitment of the US FDA for supporting a competitive marketplace for the biological products and it has also been ultimately empowering the patients by providing help in increasing the access of the patients to the high-quality, safe and effective medications at potential low cost, and these products of insulin might also be replaced by the reference product without any kind of intervention of the prescribing personnel.